Cargando…

Identification of Potential Biological Factors Affecting the Treatment of Ticagrelor After Percutaneous Coronary Intervention in the Chinese Population

BACKGROUND: Generally, many individual factors can affect the clinical application of drugs, of which genetic factors contribute more than 20%. Ticagrelor is a new class of receptor inhibitors receptor antagonist of P2Y12 and is used as an antiplatelet agents. But it is not affected by the influence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Dongdong, Shi, Xiangfen, Gao, Liping, Wan, Gaobiao, Zhang, Hanjuan, Yang, Yuling, Zhao, Yujie, Sun, Didi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786390/ https://www.ncbi.nlm.nih.gov/pubmed/35082514 http://dx.doi.org/10.2147/PGPM.S338287

Ejemplares similares

Lower Platelet Aggregation Is a Risk Factor for Dual Antiplatelet Therapy-Associated Bleeding: A Preliminary Retrospective Study with Genotype Analysis
por: Yuan, Dongdong, et al.
Publicado: (2020)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018)

Diffuse alveolar hemorrhage associated with ticagrelor therapy after percutaneous coronary intervention
por: Yılmaz, Samet, et al.
Publicado: (2018)

Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention
por: Lu, Wenbin, et al.
Publicado: (2021)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention
por: LU, YANJIAO, et al.
Publicado: (2016)

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
por: Zheng, Wei, et al.
Publicado: (2019)

A Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention: The CAPITAL RELOAD Study
por: Hibbert, Benjamin, et al.
Publicado: (2014)

Ticagrelor-induced Diarrhea in a Patient with Acute Coronary Syndrome Requiring Percutaneous Coronary Artery Intervention
por: Alomari, Mohammad, et al.
Publicado: (2019)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021)

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Wang, He-Yang, et al.
Publicado: (2018)

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
por: Marian, Moazez J., et al.
Publicado: (2017)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Successful Caesarean Section on Ticagrelor Treatment One Day after Primary Percutaneous Coronary Intervention
por: Antonijevic, Nebojsa, et al.
Publicado: (2023)

“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States
por: Larmore, Cynthia, et al.
Publicado: (2015)

One-Month Outcomes of Cases Receiving Ticagrelor after Percutaneous Coronary Intervention; a Case Series
por: Namazi, Mohammad Hasan, et al.
Publicado: (2020)

Correction: Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
Publicado: (2019)

Influence of early dose reduction of ticagrelor on clinical outcomes following percutaneous coronary intervention for complex lesions
por: Lee, Yonggu, et al.
Publicado: (2023)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
por: Fan, Zhong-Guo, et al.
Publicado: (2019)

Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease
por: Orme, Rachel C., et al.
Publicado: (2018)

Comparison of Ticagrelor Monotherapy and Ticagrelor Plus Aspirin Among Patients With Acute Coronary Syndrome Combined With High-Risk of Gastrointestinal Bleeding After Percutaneous Coronary Intervention: A Retrospective Cohort Study
por: Tian, Ming-Yu, et al.
Publicado: (2023)

Comparative study of ticagrelor and clopidogrel in therapeutic effect of acute myocardial infarction patients undergoing percutaneous coronary intervention
por: Yao, Guangtao, et al.
Publicado: (2017)

Comparison of the effects of ticagrelor and clopidogrel on heart rate variability and heart rate turbulence in patients with percutaneous coronary interventions
por: Yagcioglu, Pinar, et al.
Publicado: (2020)

Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis
por: Zhang, Wen-bin, et al.
Publicado: (2021)

Effect of Ticagrelor on Coronary Blood Flow and Prognosis in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in Real World
por: Jin, Yan-Yan, et al.
Publicado: (2018)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark
por: Thrane, Pernille Gro, et al.
Publicado: (2022)

Prasugrel versus ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: A critical appraisal of randomized controlled trials
por: Almas, Talal, et al.
Publicado: (2022)

Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007–2017)
por: Guan, Wenjun, et al.
Publicado: (2018)

Musk Tongxin Dripping Pills for treating Ticagrelor in Patients After Percutaneous Coronary Intervention: Echocardiography Combined with Untargeted Metabolomics
por: Nan, Lyu, et al.
Publicado: (2021)

Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Elderly Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study
por: Meng, Shaoke, et al.
Publicado: (2022)

Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention
por: Kim, Yuri, et al.
Publicado: (2023)

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume
por: Zhang, Yang, et al.
Publicado: (2021)

Rosuvastatin plus ticagrelor decreases the risk of major adverse cardiovascular events and elevates cardiac function compared with ticagrelor alone in patients undergoing percutaneous coronary intervention: A meta‑analysis
por: Sun, Jinling, et al.
Publicado: (2023)

Ticagrelor vs. Clopidogrel in Older Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From a Real-World Registry
por: Zhang, Yunnan, et al.
Publicado: (2022)

Effect of CYP3A4(∗)1G and CYP3A5(∗)3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects
por: Liu, Shuaibing, et al.
Publicado: (2017)

Comparison of the Infarct Size between the Loading of Ticagrelor and Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Yun, Kyeong Ho, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_92mq7aomhdegcrlt1iqnmlf8fj